Instrument Inactif

Autres langues IGI LABORIGI NYSE

Actions

Cours en clôture NYSE Autres places de cotation
- ^USD	-

26/07/22	Teligent, Inc. a fait faillite	CI
25/05/22	Deuxième motion pour la prolongation de la période d'exclusivité approuvée pour Teligent, Inc.	CI

Autres langues

05/08/22	Hikma's diversified business delivers resilient H1 performance
26/07/22	Teligent, Inc. Went Out of Business
15/07/22	Second Amended Liquidation Plan Approved for Teligent, Inc.
25/05/22	Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.
24/05/22	Second Amended Joint Liquidation Plan Filed by Teligent, Inc.
29/04/22	First Amended Disclosure Statement Approved for Teligent, Inc.
27/04/22	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.
08/04/22	Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.
01/03/22	First Motion for Exclusivity Period Extension Approved For Teligent, Inc.
23/02/22	Motion for Case Conversion Filed by Teligent, Inc.
10/02/22	First Motion for Exclusivity Period Extension Filed by Teligent, Inc.
03/02/22	Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets
03/02/22	Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).
03/02/22	Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).
19/01/22	Motion for Asset Sale Approved for Teligent, Inc.
19/01/22	Motion for Asset Sale Approved for Teligent, Inc.
19/01/22	Motion for Asset Sale Approved for Teligent, Inc.
18/01/22	Hikma expands into Canada with acquisition of Teligent sterile injectable assets
17/01/22	London Shares to Open Higher as Traders Focus On Key Data
17/01/22	Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition
17/01/22	Asset Purchase Agreement Filed by Teligent, Inc.
17/01/22	Asset Purchase Agreement Filed by Teligent, Inc.
17/01/22	Asset Purchase Agreement Filed by Teligent, Inc.
17/01/22	Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.
14/01/22	Notice of Selection of Successful Filed for Teligent, Inc.